Li Jianwei, Wei Kuanhai, Yu Hailang, Jin Dan, Wang Gang, Yu Bin
Department of Traumatology and Orthopedics, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Institute of Genetic Engineering, Southern Medical University, Guangzhou 510515, China.
Sci Rep. 2015 Dec 3;5:17903. doi: 10.1038/srep17903.
More and more studies have investigated the effects of Ezrin expression level on the prognostic role in various tumors. However, the results remain controversial rather than conclusive. Here, we performed a systematic review and meta-analysis to evaluate the correlation of Ezrin expression with the prognosis in various tumors. the pooled hazard ratios (HR) with the corresponding 95% confidence intervals (95% CI) were calculated to evaluate the degree of the association. The overall results of fifty-five studies with 6675 patients showed that elevated Ezrin expression was associated with a worse prognosis in patients with cancers, with the pooled HRs of 1.86 (95% CI: 1.51-2.31, P < 0.001) for over survival (OS), 2.55 (95% CI: 2.14-3.05, P < 0.001) for disease-specific survival (DFS) and 2.02 (95% CI: 1.13-3.63, P = 0.018) for disease-specific survival (DSS)/metastasis-free survival (MFS) by the random, fixed and random effect model respectively. Similar results were also observed in the stratified analyses by tumor types, ethnicity background and sample source. This meta-analysis suggests that Ezrin may be a potential prognostic marker in cancer patients. High Ezrin is associated with a poor prognosis in a variety of solid tumors.
越来越多的研究探讨了埃兹蛋白（Ezrin）表达水平对各种肿瘤预后的影响。然而，结果仍存在争议而非定论。在此，我们进行了一项系统评价和荟萃分析，以评估埃兹蛋白表达与各种肿瘤预后的相关性。计算合并风险比（HR）及相应的95%置信区间（95%CI）来评估关联程度。对55项研究共6675例患者的总体结果显示，埃兹蛋白表达升高与癌症患者预后较差相关，随机、固定和随机效应模型得出的总生存期（OS）合并HR为1.86（95%CI：1.51 - 2.31，P < 0.001），疾病特异性生存期（DFS）为2.55（95%CI：2.14 - 3.05，P < 0.001），疾病特异性生存期（DSS）/无转移生存期（MFS）为2.02（95%CI：1.13 - 3.63，P = 0.018）。在按肿瘤类型、种族背景和样本来源进行的分层分析中也观察到了类似结果。这项荟萃分析表明，埃兹蛋白可能是癌症患者潜在的预后标志物。埃兹蛋白水平高与多种实体瘤的不良预后相关。
Zotero 插件
